TARS
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) has 11 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jun 22, 2026.
Insiders have net sold $2.5M over the trailing 6 months.
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.5M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$2.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Azamian Bobak R.First filing | President/CEO and Board Chair | Sale | 10,000 | $615K | Jun 22 | SEC ↗ |
LINK WILLIAM J PHDFirst filing | Director | Sale | 12,500 | $776K | Jun 17 | SEC ↗ |
Farrow Jeffrey SFirst filing | See Remarks | Sale | 14,396 | $877K | Jun 17 | SEC ↗ |
Goodrich KatherineFirst filing | Director | Sale | 2,954 | $183K | Jun 17 | SEC ↗ |
Related companies
Tarsus Pharmaceuticals, Inc. is in the Healthcare sector.